NCT02751398View on ClinicalTrials.gov

Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

June 15, 2020

Study Completion Date

June 15, 2020

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Dapagliflozin 10mg

DRUG

Placebo 10mg

Matching placebo for dapagliflozin 10 mg

Trial Locations (1)

120-752

Division of Cardiology, Yonsei Cardiovascular Hospital, Yonsei University College of Medicine, Seoul

All Listed Sponsors
lead

Yonsei University

OTHER

NCT02751398 - Impact of Dapagliflozin on DIAstolic Dysfunction in Type 2 Diabetic Patients | Biotech Hunter | Biotech Hunter